Screener
CG Oncology CGON Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by CG Oncology in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: CG Oncology’s 10-Q, filed May 8, 2026.
- Filed
- May 8, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-214669
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Purchases of investments | (587,394) | (361,892) |
| Issuance of note receivable | — | (25,000) |
| Purchases of property and equipment | (304) | (16) |
| Net cash used in investing activities | (334,845) | (186,769) |
| Financing Activities | ||
| Proceeds from follow-on public offerings, net of issuance costs | 391,550 | — |
| Proceeds from exercise of common stock options | 1,669 | 682 |
| Withholding taxes paid on net exercise of stock options | (174) | — |
Item 1. Financial Statements.
FAQ
- What is CG Oncology's investing cash flow?
- CG Oncology (CGON) reported investing cash flow of -$334.85M in Q1 2026.
- How has CG Oncology's investing cash flow changed year-over-year?
- CG Oncology's investing cash flow decreased by 79.3% year-over-year, from -$186.77M to -$334.85M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about CG Oncology's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude